Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases
Maryanne Covington, Xin He, Monika Scuron, Jun Li, Robert J. Collins, Ashish Juvekar, Niu Shin, Margaret Favata, Karen Gallagher, Sarala Sarah, Chu‐Biao Xue, Michael T. Peel, Krista Burke, Julian Oliver, Brittany Fay, Wenqing Yao, Taisheng Huang, Peggy Scherle, Sharon Diamond, Robert Newton, Yan Zhang, Paul Smith
Topics & Concepts
MedicineInflammatory bowel diseaseJanus kinaseArthritisPharmacologystatTofacitinibPathogenesisRheumatoid arthritisColitisRuxolitinibDiseaseImmunologyCytokineSTAT3Internal medicineSignal transductionBone marrowBiologyMyelofibrosisBiochemistryCytokine Signaling Pathways and InteractionsAutoimmune and Inflammatory Disorders ResearchMyeloproliferative Neoplasms: Diagnosis and Treatment